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Abstract
Aim: This study aimed to examine drug use, drug treatment history and risk behaviour among a
sample of Iranian drug users seeking treatment through a general practice clinic in Iran.
Methods: Review of medical records and an intake questionnaire at a large general practice in
Marvdasht, Iran, with a special interest in drug dependence treatment. Records from a random
sample of injecting drug users (IDU), non-injecting drug users (DU) and non-drug using patients
were examined.
Results: 292 records were reviewed (34% IDU, 31% DU and 35% non-drug users). Eighty-three
percent were males; all females were non-drug users. The mean age of the sample was 30 years.
Of the IDU sample, 67% reported sharing a needle or syringe, 19% of these had done so in prison.
Of those who had ever used drugs, being 'tired' of drug use was the most common reason for
seeking help (34%). Mean age of first drug use was 20 years. The first drugs most commonly used
were opium (72%), heroin (13%) and hashish/ other cannabinoids (13%). Three quarters reported
having previously attempted to cease their drug use. IDU were more likely than DU to report
having ever been imprisoned (41% vs 7%) and 41% to have used drugs in prison.
Conclusion: This study has shown that there is a need for general practice clinics in Iran to treat
drug users including those who inject and that a substantial proportion of those who inject have
shared needles and syringes, placing them at risk of BBVI such as HIV and hepatitis C. The
expansion of services for drug users in Iran such as needle and syringe programs and
pharmacotherapies are likely to be effective in reducing the harms associated with opium use and
heroin injection.
Introduction
Opium has been consumed in Iran for at least three cen-
turies [1]. Iran is on the main opium trade route from
Afghanistan, although data on availability of opium and
opium products in Iran is limited [1]. A rapid assessment
of substance drug use in 1998/1999 found that three
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quarters of the illicit drug users interviewed used opium
and more than third use heroin [2]. There is also some evi-
dence of increased injecting drug use in Iran [2]. However,
there is currently very little known about patterns of drug
use and risks associated with injecting in Iran.
Injecting drug use is associated with a number of negative
health outcomes, including increased mortality [3] and
morbidity from overdose [4], increased risk of the drug
dependence [5], and is of considerable public health sig-
nificance due to the increased blood-borne viral infection
(BBVI) transmission [6]. HIV infection has been found to
be very high among IDUs, especially in those areas with-
out widespread harm reduction initiatives [7]. Further-
more, experience in other countries has demonstrated
that the incidence and prevalence of HIV infection can
change rapidly among injecting drug users [8]. The preva-
lence of hepatitis C is high among populations of IDUs,
and globally IDU represent the largest risk group for infec-
tion [9].
Research with Iranian volunteer blood donors found that
those with a history of injecting drug use were 53 times
more likely to be infected with HCV than other groups
[10]. A recent study of drug dependent prisoners, revealed
a HIV prevalence of 1.2% and a HCV prevalence of 47.4%
[11]. In order to be optimally cost-effective, health care
interventions aimed at reducing the spread of BBV should
be tailored to the specific risk-factors of injecting drug
users.
However, specific information on injecting drug users in
Iran, including help seeking and blood-borne virus risk
behaviour, is currently insufficient to allow such tailoring
of health promotion and intervention strategies, and to
facilitate the monitoring of risk-factor trends over time.
Therefore the aim of this paper was to examine drug use,
drug treatment history and risk behaviour among a sam-
ple of Iranian drug users seeking health care through a
general practice clinic in Iran.
Methods
The Marvdasht Clinic is a general practice clinic, with a
special interest in drug dependence and treatment in Mar-
vdasht, Shiraz, Iran. The clinic arranges general practice
services and substance abuse treatment, especially phar-
macotherapy for opioid dependence. The clinic also offers
a drop in centre for drug users every day between 8.30 am
and 7 pm.
Basic demographic information (age, gender) was col-
lected and a physical examination performed on all those
who attend the clinic. Those who reported any drug use
also completed a brief drug use questionnaire adminis-
tered by the clinician which was used in the assessment
and treatment of the patient. Information was elicited
from patients in Farsi and entered onto the forms in Eng-
lish. All data presented were collected by one clinician
(BN).
A random selection of 200 substance abusing patient
records (100 drug users and 100 injecting drug users) and
100 general patients' records were selected. Computer
generated random numbers were used to select client
records based on their registration number.
Clinic records were de-identified and data were entered
into SPSS (version 11.0). Continuous data were analysed
using t tests. Where data were highly skewed the Mann-
Whitney U statistic was used and medians reported. Cate-
gorical data are presented as proportions and were ana-
lysed using the chi square test. All data were analysed
using SPSS (version 11.0).
Results
Three thousand patients attended the clinic between 1999
and 2002. Approximately 50% attended the clinic as gen-
eral patients, 10% were injecting drug users and 40% were
drug users but not injecting.
Two-hundred and ninety-two records were selected, of
which 100 (34%) were completed on injecting drug users
(IDU), 90 (31%) were completed on drug users who did
not inject (DU) and 102 (35%) were completed on non-
drug users (i.e. general clinic clients). The sample com-
prised 241 males (83%) and 30 females. All females were
non-drug using patients. The mean age of patients was 30
years (SD 10.29). The drug using sample tended to be
younger than the other clinic patients (27 years vs 35
years, t289 = 6.83, p < 0.001).
Blood borne viruses
Blood-borne virus status was unknown for the majority of
the patients. In the 32 cases where hepatitis B status was
known, the six patients who were antibody positive, all
were IDU. In the 20 cases where hepatitis C status was
known, five patients (25%) were antibody positive and all
were IDU. Only 19 patients had their HIV status recorded,
of whom only one was positive, this patient was an IDU.
HIV risk behaviour
The majority (67%) of IDU reported having shared a nee-
dle or syringe at some time. Sixty two patients reported the
location where this took place and the most common was
somewhere other than home (44%), in prison (19%) and
at home (1%).Harm Reduction Journal 2006, 3:2 http://www.harmreductionjournal.com/content/3/1/2
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Drug using clients only (n = 190)
Drug use history
The mean age of first drug use was 20 years (SD 4.80). The
IDUs tended to be younger at first drug use than the DUs
(19 years vs 22 years, t186 = 5.08, p < .001).
Opium was the drug most commonly first used (72%),
followed by heroin (13%) and hashish or another can-
nabinoid (13%). Four patients (2%) reported buprenor-
phine as the drug they first used.
Patients were most commonly with friends (38%) at the
time of first drug use, with family (28%) or at work
(22%). Fifteen patients (8%) reported first using drugs in
military service and eight (4%) reported being in prison
when they first used drugs.
Opium was the primary drug for half the patients (50%),
followed by heroin (43%). A small proportion reported
buprenorphine as their primary drug (6%).
Reason for attending the clinic
The majority (73%) of drug using patients did not state a
reason for attending the clinic. Of the remaining 51
patients who stated a reason for attending the clinic, the
main reason given was related to family issues (36
patients), followed by 'compulsory testing' (11 patients)
and court (3 patients).
Family drug use history and support
A third of patients (31%) identified a family member who
also used drugs. Of those 59 patients, a sibling (63%) or a
parent (32%) were the most commonly identified rela-
tive. A history of drug use in the patient's parents' family
was identified by 78 patients; this was most commonly
identified in the patient's mother's family (65%).
The majority of drug using patients (92%) reported hav-
ing drug using friends; 80% reported that they had at least
two drug using friends. Of the 174 patients with drug
using friends 131 (75%) reported still having contact with
these drug using friends.
Only 10 patients (5%) reported having no family support.
Of the 180 patients who reported having family support,
34% identified a sibling as providing this support, 32%
identified their spouse, 31% identified a parent and four
patients (2%) identified their child as providing support.
Ceasing drug use
Patients were asked about the most important reason for
ceasing their drug use. Being 'tired' (of using drugs) was
the most common response (34%), followed by work rea-
sons (21%; included having lost their job as a result of
drug use), family (17%) and marriage (2%). 'Other' rea-
sons were nominated by 40 patients, 10 of which were
related to health, others included being sent for compul-
sory testing, having a driver's licence revoked or a work/
study issue.
Drug treatment
Almost three quarters of patients reported having previ-
ously attempted to cease their drug use. Of these, 11% had
attempted to cease drug use once, while the majority
(75%) had made several attempts and had done so a
median of two times (range 1–10). There was no differ-
ence between the IDUs and DUs in terms of number of
attempts to cease drug use.
Of the 146 patients who had attempted to cease drug use
and received help, 36% received help from their spouse,
25% from a sibling, 19% from a friend and 18% from a
parent. Twenty patients (12%) reported receiving no help
or support during their attempts to cease drug use.
Patients reported using a variety of drugs to assist with
drug use cessation in including homemade capsules
(95%), drugs such as benzodiazepines, opiates such as
black water opium, methadone, morphine and various
other opium compounds (63%).
Of those who had previously attempted to cease drug use,
17 (10%) had remained abstinent for less than a week.
The median number of weeks abstinent for the 147
patients who reported a week or more of abstinence was
eight (range 1150;104). DU reported being abstinent for
significantly more weeks than IDU (Mann-Whitney U
1705, p < .001).
Reasons cited for patient relapse included health prob-
lems (55%), withdrawal (39%), drug craving (32%) and
a range of other symptoms (26%) such as insomnia, loss
of energy, anxiety and depression, pain, irritability and
sexual dysfunction.
Prison
Forty-five (24%) of the patients had a history of incarcer-
ation. IDU were more likely to have been to prison than
DU (41% vs 7%, χ2 = 29.7, p < 0.001). Forty-one patients
(91% of those ever imprisoned) reported having used
drugs while in prison. All DUs and 85% of IDU who
reported having been to prison used drugs in prison. The
drugs used in prison were opium (55%), heroin (20%)
and hashish/ cannabis (9%). Only one patient reported
receiving drug treatment in prison.
Discussion
This study found that Iranian drug users seeking treatment
for drug use problems most commonly use opium and
heroin. Drug users presenting at this clinic tended to beHarm Reduction Journal 2006, 3:2 http://www.harmreductionjournal.com/content/3/1/2
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younger than clients presenting with non drug-related
problems. None of the drug using patients in this study
were female. There is limited information on the preva-
lence of drug use among Iranian women, and it is unclear
whether the lack of female drug users in this clinic sample
is due to a very low prevalence of problematic drug use
among women in Iran or that they are more likely to con-
stitute a 'hidden' population and are unwilling to attend
for treatment. Other studies of Iranian drug users also
reported few females [e.g. [12]]. Reports from western
countries has shown that drug use has been associated
with greater stigmatisation, reduced service utilisation
[e.g. [13]] and different treatment seeking behaviours [e.g.
[14]] for women than men.
The majority of patients had previously attempted to
cease drug use; traditionally drug treatment in Iran has
comprised abrupt cessation without medication or slow
decrease in heroin /opium dose [15]. This study has dem-
onstrated that Iranian drug users are willing to seek med-
ical treatment for their drug dependency. Buprenorphine
has been shown to be effective in the treatment of Iranian
heroin [12] and opium [15,16] users but needs to be more
widely available, especially through general practice clin-
ics, such as that described here as it may reduce stigmati-
sation for the user. It may be necessary to establish a
special clinic for female drug users with female staff to
encourage them to seek treatment.
Of the IDU sample, more than two thirds reported sharing
needles and syringes and therefore placing themselves at
considerable risk of HIV and hepatitis C infection. Needle
and syringe programs have been shown to reduce the
prevalence of HIV [17,18], and in settings with accessible
needle and syringe program and health promotion initia-
tives, have also been shown to reduce needle and syringe
sharing [19,20]. Although NSP programs have been intro-
duced to Iran, the programs are small in number and still
in their infancy.
A quarter of the drug users in the study had a history of
imprisonment, with injectors much more likely to report
this, almost all of whom reported injecting drug in pris-
ons. Prisons have been identified as a high risk environ-
ment [21,22]. Almost half the sample of incarcerated
IDUs in a recent Iranian study reported having ever shared
a needle /syringe compared to 18% of non-incarcerated
IDUs [23]. Moreover, only one patient reported receiving
treatment for drug use in prison. The Iranian prison
department is in the process of developing a strategic plan
for prisons. Recent research has shown that the provision
of methadone maintenance in prison can reduce injecting
drug use and hepatitis C infection [24].
Drug treatment services provide a useful point for HIV
and other BBVI monitoring [25,26]. Clinics should try to
collect complete data for each patient attending the clinic
in order to better inform the service. For example, for 73%
of patients no reason was given for attending the clinic. It
would be useful to know why clients come to clinics so
their anticipated needs can be met and retention
improved in treatment or with services. Moreover, routine
collection of data from services, including small inde-
pendent units such as that described in the current study,
provides useful information for treatment outcome mon-
itoring [27]. Similar Australian practices have, for exam-
ple, been able to provide information on treatment
outcomes in terms of decreased heroin use (as measured
by self-report and urinalysis) and increased employment
[28], and more recently report on the impact of metha-
done maintenance on hepatitis C incidence [29].
Finally, this study has shown that Iranian drug users seek-
ing treatment through a GP clinic predominantly use
opium and heroin. Of those who inject drugs, the major-
ity has shared needles and syringes, placing them at risk of
HIV, hepatitis B and hepatitis C. The expansion of services
for drug users in Iran such as needle and syringe programs
and pharmacotherapies such as buprenorphine are likely
to be effective in reducing the harms associated with
opium use and the increasing problem of heroin injec-
tion.
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